| CPC A61M 1/3486 (2014.02) [A61B 5/412 (2013.01); A61M 2205/0277 (2013.01)] | 24 Claims |
|
1. A method for extracorporeal treatment of a body fluid of a patient suffering from a dysregulated immune response, in an extracorporeal flow line, comprising removing at least one harmful substance from the body fluid of the patient, comprising the following steps:
at least a first injection step, in which, by means of a first injection device, a first mixture containing functionalized magnetic particles bound to at least a first binding agent at least directed against a first type of target molecules contained in the body fluid is added to the extracorporeal flow line comprising a sample of the body fluid extracted from the patient suffering from the dysregulated immune response, e.g. sepsis, and containing at least the first type of target molecules, in a therapeutically effective dose necessary to reduce a concentration of the target molecules of at least the first type in the sample of body fluid of the patient,
subsequently, mixing the body fluid comprising the functionalized magnetic particles to ensure sufficient binding of the target molecules of at least the first type to the functionalized magnetic particles; and
separating the functionalized magnetic particles bound to the target molecules of at least the first type from the sample of body fluid, such that a concentration of target molecules of at least the first type in the sample of body fluid is reduced,
wherein the method further comprises at least a second injection step, in which, by means of a second injection device, a second mixture different from the first mixture and containing functionalized magnetic particles, is added to the extracorporeal flow line comprising the body fluid extracted from the patient,
wherein the second injection step is carried out downstream of or simultaneously with the first injection step,
wherein in the second injection device, the functionalized magnetic particles contained in the second mixture are bound to a second binding agent different from the first binding agent and directed against a second type of target molecule contained in the body fluid and different from the first target molecule, or wherein in the second injection device the functionalized magnetic particles contained in the second mixture are bound to the first binding agent but are present in a different concentration in the second mixture than in the first mixture;
and wherein the method further comprises, upstream of the first injection step, a diagnostic step, in which data providing information about an immunological status of the patient is obtained by measuring an expression of at least one marker molecule or a concentration of at least one marker molecule in the body fluid of the patient in an assay or by a sensor,
and wherein the data obtained in the diagnostic step from the patient's body fluid providing information about the immunological status of the patient is transmitted to a control unit which is arranged in an electrical or wireless communication with the extracorporeal circuit,
and wherein the control unit individually controls the first injection step and the second injection step based on the data providing information about the immunological status of the patient and in terms of at least one of the following: type of binding agent, injection rate, time of injection, injection dose, injection concentration, and/or injection pressure,
wherein the injection of the second mixture by the second injection device is controlled separately, but in coordination with the injection of the first mixture by the first injection device.
|